SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

RPG Life Sciences - Quaterly Results

02 Aug 2022 Evaluate
The company witnessed a 19.24% growth in the revenue at Rs. 1289.30 millions for the quarter ended June 2022 as compared to Rs. 1081.30 millions during the year-ago period.Net Profit recorded in the quarter ended June 2022 rise to 34.09% to Rs. 182.10  millions  compared to R. 135.80 millions in corresponding previous quarter.OP of the company witnessed a marginal growth to 290.60 millions from 233.60 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1289.30 1081.30 19.24 1289.30 1081.30 19.24 4401.60 3891.40 13.11
Other Income 12.20 4.10 197.56 12.20 4.10 197.56 29.90 9.10 228.57
PBIDT 290.60 233.60 24.40 290.60 233.60 24.40 893.50 708.40 26.13
Interest 1.10 1.30 -15.38 1.10 1.30 -15.38 5.20 7.90 -34.18
PBDT 289.50 232.30 24.62 289.50 232.30 24.62 888.30 700.50 26.81
Depreciation 38.30 39.60 -3.28 38.30 39.60 -3.28 156.60 164.70 -4.92
PBT 251.20 192.70 30.36 251.20 192.70 30.36 731.70 535.80 36.56
TAX 69.10 56.90 21.44 69.10 56.90 21.44 216.90 135.80 59.72
Deferred Tax 3.30 -0.90 -466.67 3.30 -0.90 -466.67 -10.70 -35.70 -70.03
PAT 182.10 135.80 34.09 182.10 135.80 34.09 514.80 400.00 28.70
Equity 132.30 132.30 0.00 132.30 132.30 0.00 132.30 132.30 0.00
PBIDTM(%) 22.54 21.60 4.33 22.54 21.60 4.33 20.30 18.20 11.51

RPG Life Sciences Share Price

2299.65 -3.65 (-0.16%)
24-Jun-2026 13:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1877.60
Dr. Reddys Labs. 1336.50
Cipla 1442.00
Zydus Lifesciences 1101.45
Lupin 2382.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: